Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-19T11:48:52.068Z Has data issue: false hasContentIssue false

N-terminal mutations in the anti-estradiol Fab 57-2 modify its hapten binding properties

Published online by Cambridge University Press:  10 February 2001

PETRI SAVIRANTA
Affiliation:
Department of Biotechnology, University of Turku, Tykistökatu 6A, Turku FIN-20520, Finland
PIITU JAURIA
Affiliation:
Department of Biotechnology, University of Turku, Tykistökatu 6A, Turku FIN-20520, Finland Current address: Innotrac Diagnostics Oy, Tykistökatu 4D, Turku FIN-20520, Finland.
URPO LAMMINMÄKI
Affiliation:
Department of Biotechnology, University of Turku, Tykistökatu 6A, Turku FIN-20520, Finland
JUKKA HELLMAN
Affiliation:
Centre for Biotechnology, Tykistökatu 6, Turku FIN-20521, Finland.
SUSANN ERIKSSON
Affiliation:
Department of Biotechnology, University of Turku, Tykistökatu 6A, Turku FIN-20520, Finland
TIMO LÖVGREN
Affiliation:
Department of Biotechnology, University of Turku, Tykistökatu 6A, Turku FIN-20520, Finland
Get access

Abstract

Recombinant antibodies often contain N-terminal mutations arising from the use of degenerate cloning primer sets and/or the introduction of restriction sites in the framework 1 regions. We studied the effects of such mutations in a recombinant anti-estradiol Fab fragment derived from the hybridoma cell line 57-2. The 5′ ends of the heavy and light chain genes were originally modified to introduce the restriction sites XhoI and SacI, respectively, for cloning purposes. However, the affinity and specificity of the recombinant Fab were lowered compared to the proteolytic Fab′ fragment of the parental hybridoma IgG. Replacing the mutated sites with authentic amino acid coding sequences restored the binding properties as well as increased the bacterial production levels fivefold and 10-fold at 30 and 37 °C, respectively. Local changes in the antigen binding site were probed by determining the affinity constants (Ka) for estradiol and four related steroids. It was found that the mutated heavy chain amino terminus specifically increased the Ka for testosterone whereas the mutated light chain amino terminus decreased the Ka for all of the steroids to the same extent; the heavy and light chain effects were additive. Analysis of a newly determined crystal structure of the authentic Fab 57-2 in complex with estradiol suggests that mutations in the residue 2 in VH, and 2 and 4 in the VL domain were those responsible for the observed effects. Their general roles as structure-determining residues for the CDR3 loops imply that similar effects can occur with other recombinant antibodies as well.

Type
Research Article
Copyright
© 2000 The Protein Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)